We are live on ! Find out more
HTGM

HTG Molecular Diagnostics, Inc. Common Stock
HTGM

Delisted

HTGM was delisted on the 14th of June, 2023.

Back to rankings

27 hedge funds and large institutions have $13.3M invested in HTG Molecular Diagnostics, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 6

11% less capital invested

Capital invested by funds: $15M → $13.3M (-$1.66M)

39% less funds holding

Funds holding: 44 → 27 (-17)

77% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 22

Holders
27
Holders Change
-17
Holders Change %
-38.64%
% of All Funds
0.53%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
8
Reduced
6
Closed
22
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CPA
Cowen Prime Advisors
New York
+$1.53M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$211K
3
PCM
Perkins Capital Management
Minnesota
+$131K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$107K
5
First Manhattan
First Manhattan
New York
+$75.3K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.83M
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$922K
3
SCM
Stonepine Capital Management
Oregon
-$776K
4
SCM
Sio Capital Management
New York
-$199K
5
DC
Diametric Capital
Massachusetts
-$179K
Name Holding Trade Value Shares
Change 		Change in
Stake
IF
26
Ironwood Financial
Arizona
$1K – – –
Fidelity Investments
27
Fidelity Investments
Massachusetts
– -$1.83M -14,961 Closed
Alyeska Investment Group
28
Alyeska Investment Group
Illinois
– -$922K -7,709 Closed
SCM
29
Sio Capital Management
New York
– -$199K -1,667 Closed
DC
30
Diametric Capital
Massachusetts
– -$179K -1,499 Closed
PCM
31
Prelude Capital Management
New York
– -$106K -884 Closed
NIM
32
NXG Investment Management
Texas
– -$88K -736 Closed
CPP
33
Crow Point Partners
Massachusetts
– -$29K -260 Closed
Millennium Management
34
Millennium Management
New York
– -$30K -250 Closed
Renaissance Technologies
35
Renaissance Technologies
New York
– -$29K -242 Closed
FM
36
Fondren Management
Texas
– -$27K -224 Closed
Bank of America
37
Bank of America
North Carolina
– -$23K -190 Closed
Bank of New York Mellon
38
Bank of New York Mellon
New York
– -$17K -139 Closed
Citadel Advisors
39
Citadel Advisors
Florida
– -$16K -131 Closed
ARTA
40
A.R.T. Advisors
New York
– -$15K -123 Closed
Fisher Asset Management
41
Fisher Asset Management
Washington
– -$13K -106 Closed
Deutsche Bank
42
Deutsche Bank
Germany
– -$11K -99 Closed
MWM
43
Merriman Wealth Management
Washington
– -$10K -83 Closed
HR
44
Hayden Royal
North Carolina
– -$8K -67 Closed
RJFSA
45
Raymond James Financial Services Advisors
Florida
– -$8K -64 Closed
TRCT
46
Tower Research Capital (TRC)
New York
– -$8K -63 Closed
Commonwealth Equity Services
47
Commonwealth Equity Services
Massachusetts
– -$6K -56 Closed
Victory Capital Management
48
Victory Capital Management
Texas
– -$3K -23 Closed
1
2

HTGM Hedge Fund Activity: Q4 2019 in Review

27 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in HTG Molecular Diagnostics, Inc. Common Stock (HTGM) for Q4 2019, worth a combined $13.3M — down 11% from $15M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of HTGM and 5 opened new positions — a net loss of 17 holders — while 6 trimmed existing stakes and 8 added.

The largest buyer was Cowen Prime Advisors, adding an estimated $1.53M. The largest seller was Fidelity Investments, exiting entirely with an estimated $1.83M sold.

  • 27 institutional investors held HTG Molecular Diagnostics, Inc. Common Stock (HTGM) as of Q4 2019, down from 44 in Q3 2019.
  • Funds reported $13.3M of HTG Molecular Diagnostics, Inc. Common Stock stock for Q4 2019, down 11% quarter-over-quarter.
  • 5 funds opened new HTG Molecular Diagnostics, Inc. Common Stock positions in Q4 2019 and 22 closed out, a net change of -17 holders.
  • The largest HTG Molecular Diagnostics, Inc. Common Stock buyer in Q4 2019 was Cowen Prime Advisors, an estimated $1.53M added.
  • The largest HTG Molecular Diagnostics, Inc. Common Stock seller in Q4 2019 was Fidelity Investments, an estimated $1.83M sold.

Based on aggregated 13F filings for Q4 2019.